Articles Published in 2013

inVentiv Health Clinical launches physician network for late-stage research

Tuesday, September 24, 2013 12:43 PM

inVentiv Health Clinical, a global supplier of drug development services, has launched a web-based network to connect physicians interested in participating in late-stage research to appropriate clinical trials.

More... »

Quintiles closes Novella Clinical acquisition

Monday, September 23, 2013 01:40 PM

Global CRO Quintiles has completed its previously announced acquisition of Novella Clinical, a full-service CRO focused primarily on emerging oncology as well as medical devices and diagnostics.

More... »

H3 Biomedicine, Selvita collaborate

Monday, September 23, 2013 01:39 PM

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical company specializing in  discovering and developing precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and feasibility of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

Catalent, Supernus partner for supply of Trokendi XR

Monday, September 23, 2013 01:38 PM

Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, and Supernus Pharmaceuticals have entered into an agreement by which Catalent is the supplier of Trokendi XRTM extended release capsules for Supernus.

More... »

Ablynx, AbbVie enter global license agreement for inflammatory diseases

Monday, September 23, 2013 01:37 PM

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, and AbbVie have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

More... »

ClinTec International a finalist in SCRIP 2013 ‘Best CRO’ award

Monday, September 23, 2013 01:34 PM

Global CRO ClinTec International is a finalist for “Best CRO” at the SCRIP Awards 2013, to be held in London’s Lancaster Hotel Nov. 21.

More... »

KaloBios publishes KB001 phase I study results

Monday, September 23, 2013 01:33 PM

KaloBios Pharmaceuticals has published phase I study results for KB001, a first-generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody for use in patients with cystic fibrosis (CF). Data from this initial single-dose clinical study support the continuation of KaloBios' ongoing phase II study of KB001-A, a second-generation, anti-TTSS antibody in CF patients with chronic Pa infections.

More... »

PPD names VP for global product development

Monday, September 23, 2013 01:30 PM

CRO PPD has appointed Gregory Dennis, M.D., vice president of global product development. Dennis will be therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

More... »

Perrigo appoints Keith Webber head of regulatory review

Monday, September 23, 2013 09:46 AM

Perrigo has appointed Keith Webber head of regulatory review, effective Oct. 21. This new role will have responsibility for advancing the approval of all of Perrigo's Consumer Healthcare (CHC) and Prescription Pharmaceutical (Rx) regulatory applications pending with the FDA, providing guidance on scientific and regulatory strategy for new CHC and Rx pipeline products under development and continuously advancing the quality of new regulatory applications. 

More... »

GSK inks agreement with BARDA to supply anthrax treatment

Friday, September 20, 2013 11:32 AM

GlaxoSmithKline has signed a new four-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The U.S. government is purchasing the medicine as a counter measure against a potential bioterrorist attack.

More... »